CARD19

Across TCGA pan-cancer cohorts, CARD19 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CARD19 data layer compared with 30 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CARD19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CARD19 expression acts as an unfavorable survival marker.

THYM, COAD, and LUAD are the cancer types where CARD19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
COAD	OS	Median	All	0.233	0.806	.017	12	view →
LUAD	DFS	Median	II,III,IV	0.206	0.681	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CARD19–THYM (OS)

Open the THYM breakdown →